Replies to post #126623 on Biotech Values

[mcbio]

I do not think it is such a hot idea to pursue oncology when they have no oncology expertise

Arguably their most important asset is now in Salix's hands and their next most viable asset is in oncology. I don't know what else they would focus on if it weren't oncology given the PSMA ADC in Phase 1 and the dual PI3K/MNK inhibitor at the pre-clinical stage.